Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast
Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News21 hours agoBrisbane Broncos star Reece Walsh says punching friend in face ‘not a good look’
-
General14 hours agoDairy farmers devastated by floods across parts of New South Wales